A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
This record was last updated January 29, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-01; most recent amendment 2025-01-28.
Status change: Not Yet Recruiting → Recruiting2024-01-29